12 November 2014: Consort is pleased to announce that it has today completed the acquisition of Aesica Holdco Limited (“Aesica”).
As previously stated, the Board considers that the Acquisition represents an excellent opportunity for Consort and is directly in line with Consort’s articulated strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain.
Aesica is one of Europe’s leading pharmaceutical Contract Development and Manufacturing Organisations (“CDMO”), providing contract development and manufacturing services for Finished Dose and Active Pharmaceutical Ingredients to the global pharmaceutical industry. Since the Aesica business was established in 2004, it has grown both organically and through acquisitions and has established key strategic relationships with major global blue-chip pharmaceutical companies.
Jon Glenn, Consort’s Chief Executive Officer, said:
“We are excited by the acquisition of Aesica which represents a very strong fit with our existing strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain. As one of Europe’s leading pharmaceutical CDMOs, Aesica is highly complementary to Bespak’s existing business and provides a number of clear strategic, competitive and value-enhancing benefits for the Enlarged Group.”
Capitalised terms not defined herein, are defined at Part XVIII of the combined shareholder prospectus and circular published by the Company on 30 September 2014.
Help employers find you! Check out all the jobs and post your resume.
